Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus alternative administration route of combined MeMuRu-OKA vaccine [MMR varicella zoster virus vaccine] to healthy children aged 11 to 21 months

Trial Profile

Open, multicenter, randomised, controlled phase IIIb study evaluating the immunogenicity and safety of subcutaneous versus alternative administration route of combined MeMuRu-OKA vaccine [MMR varicella zoster virus vaccine] to healthy children aged 11 to 21 months

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary)
  • Indications Measles; Mumps; Rubella; Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Aug 2010 Results published in the European Journal of Pediatrics.
    • 10 Mar 2008 Status changed from in progress to completed. Updated from ClinicalTrials.gov.
    • 02 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top